New non-opioid painkiller Journavx approved by US FDA
The US Food and Drug Administration (FDA) approves a new non -opioid analgesic drug that aims to treat short -term pain in adults.
The drug SUZETRIGINE is famous for its brand Journavx and is known for its targeted pain signal.
Its manufacturer Vertex Pharmaceuticals said it can effectively relieve it for moderate to severe pain without “addiction potential of opioids.”
For many years, the United States has been working hard to deal with the crisis of painkillers. In 2017, US President Trump claimed that it was “national shame” and announced the emergency of public health.
FDA said clinical trials show that Jounavx reduces the pain after surgery and claims that it is “important public health milestone in acute pain management.”
According to data from the American Disease Control and Prevention Center (CDC), every year, thousands of Americans die from the use of opioids, of which 82,000 people die in 2022.
Now in the second term, President Trump has already It is said that he will attack imports from Canada and Mexico at a 25 % border tax To some extent, a large number of fennis-a powerful synthetic opioid drug-crossed the country.
The president also threatened to impose tariffs on China, because the country’s Fentany export is the reason.
Opioid By stimulating the work of an opioid drug receptor in the brain, the pain signal is blockedEssence
In this process, the brain is also full of neurotransmitter dopamine, creating a happy feeling and activating the brain’s reward system.
This makes opioid drugs highly addicted. It is estimated that nearly 10 % of patients with acute pain were first treated with opioid drugs will continue to use.
But Journavx works differently, Stop the pain signal by arriving by the pain signal before reaching the brain.
Vertex said the drug was the first drug in the new analgesic drugs for more than 20 years.
His CEO Reshma Kewalramani said that he approved “a historical milestone of 80 million people in the United States, and they are prescribed with medium to severe acute pain every year.”
Journavx per capita price is $ 15.50 (£ 12.50), The company said, In addition, it is not known whether the drug is “effective for children.”
